Fig. 2.

Annualised relapse rates (ARR) during the 12 months before treatment commencement (before treatment), 12 months before treatment cessation (during treatment) and 12 months after treatment cessation (after cessation). The black line shows the mean relapse rate for the whole cohort, with the shaded area indicating a 95% bootstrapped bias corrected and accelerated confidence intervals. Points with whiskers show the relapse rates stratified by the class of immunotherapy started in the 12 months following cessation (high efficacy, low efficacy or none)